Bill
Bill > HR7828
summary
Introduced
05/18/2022
05/18/2022
In Committee
05/18/2022
05/18/2022
Crossed Over
Passed
Dead
01/03/2023
01/03/2023
Introduced Session
117th Congress
Bill Summary
A BILL To amend the Public Health Service Act to shorten the exclusivity period for brand name biological products from 12 to 5 years.
AI Summary
This bill, the Price Relief, Innovation, and Competition for Essential Drugs Act (PRICED Act), aims to amend the Public Health Service Act to shorten the exclusivity period for brand-name biological products from 12 years to 5 years. This change is intended to facilitate earlier competition from generic or biosimilar versions of these products, potentially leading to lower prices and increased access to essential drugs. The bill applies only to biological products licensed under the Public Health Service Act on or after the date of the bill's enactment.
Committee Categories
Business and Industry
Sponsors (11)
Jan Schakowsky (D)*,
Rosa DeLauro (D),
Lloyd Doggett (D),
Chuy García (D),
Pramila Jayapal (D),
Marcy Kaptur (D),
Ro Khanna (D),
Raja Krishnamoorthi (D),
Andy Levin (D),
Mark Pocan (D),
Bruce Westerman (R),
Last Action
Referred to the House Committee on Energy and Commerce. (on 05/18/2022)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/117th-congress/house-bill/7828/all-info |
| BillText | https://www.congress.gov/117/bills/hr7828/BILLS-117hr7828ih.pdf |
| Bill | https://www.congress.gov/117/bills/hr7828/BILLS-117hr7828ih.pdf.pdf |
Loading...